---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-028103"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:48:02.210886+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics raises $17M via Atlas note to partially repay Avondale debt; going concern warning

## Summary
- Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.
- Remaining Avondale Note balance of ~$10.8M; maturity extended to Dec 31, 2026 via amendment.
- Atlas note: interest prime+3% (floor 9.5%), matures 15 months from March 16, 2026; quarterly redemption up to $3M; 7.5% exit fee.
- Supplemental risk factors state substantial doubt about going concern; cash insufficient for next 12 months.
- FDA issued third Complete Response Letter for ONS-5010 in Dec 2025; Type A meeting held March 2026 with no clear path.

## SEC filing metadata
- accession: 0001104659-26-028103
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/0001104659-26-028103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-028103
- JSON: https://secwatch.observer/filing/0001104659-26-028103.json
- Plain text: https://secwatch.observer/filing/0001104659-26-028103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.